biotech · Ovarian Clear Cell Carcinoma · Tumors · LIXT
LIXTE BIOTECHNOLOGY HOLDINGS
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Lixte Biotechnology Holdings is a biotech organization headquartered in East Setauket, USA. It trades on NYSE under ticker LIXT. Primary therapeutic focus areas include Ovarian Clear Cell Carcinoma, Tumors, Myelodysplast
East Setauket, USA HQ
2006 Founded
7 Employees
Public company Type
LIXT · NYSE Ticker
Company details
- Status
- Public
- HQ
- East Setauket, USA
- Founded
- 2006
- Employees
- 7
- Programs
- 3
- Drugs
- 3
- Patents
- 26
LB-100
Phase 2 · small molecule · Myelodysplastic Syndromes
LB-100 for Myelodysplastic Syndromes is a Phase 2 program (small_molecule) at LIXTE BIOTECHNOLOGY HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Internal code MCC-19635
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Myelodysplastic Syndromes
- Status
- active
- Trials
- 1